Figure 2.
Overall study design. 12 E-Series and 8 P-Series glycol ethers (plus ethylene glycol and propylene glycol) were screened in a phenotypic and transcriptomic in vitro screening approach using human iPSC-derived cardiomyocytes and hepatocytes, as well as a population-based human lymphoblast cell model. Functional and high-content imaging data was analyzed for concentration-response and resulting Point-of-Departure values were integrated into bioactivity profiles and served as a basis for sample selection for targeted transcriptomics analysis using the TempO-seq assay. Both phenotypic screening and transcriptomics data were used for comprehensive biological data-integrative grouping of the glycol ethers.